Table 2.
Baseline characteristics according to the occurrence of acute organ failure
| Characteristic | No AOF n = 172 | AOF n = 113 | p value |
|---|---|---|---|
| Age (years) | 59.6 ± 11.8 | 62.9 ± 11.6 | 0.03 |
| Male sex | 84 (48.8) | 61 (54.0) | 0.40 |
| Adjusted CCI | 0.04 | ||
| 0 | 22 (12.8) | 9 (8.0) | |
| 1 | 37 (21.5) | 15 (13.4) | |
| 2 | 35 (20.3) | 18 (16.1) | |
| ≥ 3 | 78 (45.3) | 70 (62.5) | |
| Number of daily drugs in current use | |||
| 0 | 19 (11.0) | 11 (9.8) | 0.82 |
| 1 - 5 | 95 (55.2) | 60 (52.7) | |
| ≥ 5 | 58 (33.7) | 42 (37.5) | |
| Neoplasia, type | 0.007 | ||
| Nonhematologic | 150 (87.2) | 84 (74.3) | |
| Hematologic | 22 (12.8) | 29 (25.7) | |
| Primary topography of nonhematologic tumors | |||
| Digestive tract and digestive glands | 45 (30.0) | 17 (20.2) | 0.26 |
| Lungs and respiratory tract | 22 (14.7) | 23 (27.4) | |
| Breast | 27 (18.0) | 14 (16.6) | |
| Head and neck | 9 (6.0) | 5 (6.0) | |
| Gynecologic | 9 (6.0) | 5 (6.0) | |
| Others* | 38 (25.3) | 20 (23.8) | |
| Previous antineoplastic treatment | 0.08 | ||
| Curative intent | 39 (22.7) | 37 (32.7) | |
| Palliative intent | 133 (77.3) | 76 (67.3) | |
| Time since last treatment (days) | 16 [0 - 56] | 17 [0 - 56] | 0.88 |
| > 1 previous treatment lines | 107 (62.2) | 53 (46.9) | 0.015 |
| Time since diagnosis (months) | 18,5 [0 - 178] | 11 [0 - 253] | 0.03 |
| Inpatient admission cause | |||
| Infection | 54 (31.4) | 62 (54.9) | < 0.001 |
| Febrile neutropenia | 23 (13.4) | 26 (23) | |
| Sepsis/septic shock | NA | 35 (31) | |
| Uncontrolled pain | 26 (15.1) | 6 (5.3) | |
| Respiratory insufficient (not infectious) | 5 (2.9) | 12 (10.6) | |
| Neurologic dysfunction (not infectious) | 6 (3.5) | 9 (8.0) | |
| General status degradation | 12 (7.0) | 3 (2.7) | |
| Other causes† | 69 (40.1) | 21 (18.6) | |
| Artificial organ replacement therapy | |||
| Withheld | 113 (65.7) | 59 (34.3) | 0.12 |
AOF - acute organ failure; CCI - Charlson comorbidity index; NA - not applicable.
*
Mesothelial or soft tissue, male genital organs, urinary tract, skin, thyroid or other endocrine glands, bone and articular cartilage, ill-defined, secondary and unspecified sites, neoplasms of independent (primary) multiple sites; † gastrointestinal disturbances, hemorrhage, hepatic failure, kidney failure, electrolytic disturbances, pancytopenia, cardiac failure or other cardiac causes, cord compression syndrome, mucositis, superior vena cava syndrome, anemia.
*
and † frequency less than 5%. Results expressed as mean ± standard deviation, n (%) or median [range].